Sourcing human beta cells may soon no longer be a challenge for AstraZeneca diabetes researchers thanks to a new partnership with stem cell scientists at Harvard University. The Anglo-Swedish drugmaker announced its partnership with the Harvard Stem Cell Institute today, explaining the collaboration will focus on converting stem cells into human beta cells for use in its diabetes drug candidate screening programme.
http://ift.tt/19V0nWk?
http://ift.tt/19V0nWk?
No comments:
Post a Comment